USABiotech & Genomic Medicine▲
ABIVAX Soars on Positive Ulcerative Colitis Trial Data, ProMIS and Others Gain
ABIVAX Société Anonyme surged 38.6% after reporting positive results from Part 2 of its Phase 3 ABTECT Maintenance trial of Obefazimod for moderate-to-severe ulcerative colitis, showing meaningful clinical benefits in hard-to-treat patients and strengthening the drug's long-term safety profile. The company also announced a $600 million underwritten public offering of American Depositary Shares. ProMIS Neurosciences rose 22.4% with no specific news, as investors await 6-month interim data from the PRECISE-AD Phase 1b trial in early Q3 2026. Cuprina Holdings gained 45.7% following last month's FDA clearance of its MEDIFLY Maggots for wound debridement. First Tracks Biotherapeutics climbed 18.3%, with top-line data from its ANB033 celiac disease trial expected in Q4 2026. SS Innovations International advanced 17.9% after winning an industry award and reporting 11,719 cumulative procedures with its SSi Mantra surgical robotic system.
About megatrends
Biotech & Genomic Medicine › Regenerative Medicine & Tissue Engineering ▲Regulation
Robotics & Physical AI › Surgical & Medical Robotics ▲Competition
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative Competition
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Technology
ABVX.PA · Technology · Positive Positive Phase 3 trial data for Obefazimod in ulcerative colitis
ABVX.PA · Capital · Negative Announced $600 million public offering, diluting existing shareholders
CUPR · Regulation · Positive FDA clearance of MEDIFLY Maggots for wound debridement
SSII · Demand · Positive Won industry award and reported 11,719 cumulative procedures with SSi Mantra system
PMN · · Neutral No specific news; investors await interim data in early Q3 2026
TRAX · · Neutral Mentioned only as expecting top-line data in Q4 2026; no news yet